Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.

Manish R. Patel,Susanna Varkey Ulahannan,Scott Weir,Robyn Wood,Tammy Ham,Crista Casey,Greg Reed,Prasad Dandawate,Prabhu Ramamoorthy,Michael Baltezor,Roy A. Jensen,Benjamin L. Woolbright,John A. Taylor,Shrikant Anant,Michael Dalton,Valentina Zhukova-Harrill,William McCulloch,Suzanne F. Jones,Howard A. Burris,Gerald Steven Falchook

Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.

2020

518Background: Fosciclopirox (CPX-POM) is being developed for the treatment of non-muscle invasive and muscle invasive bladder cancer. CPX-POM selectively delivers its active metabolite, ciclopirox...

Keywords:

Pathology
Ciclopirox
Pharmacology
Active metabolite
Bladder cancer
Pharmacokinetics
Medicine
muscle invasive
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations